APO-CABERGOLINE TABLET Kanada - angličtina - Health Canada

apo-cabergoline tablet

apotex inc - cabergoline - tablet - 0.5mg - cabergoline 0.5mg - ergot-derivative dopamine receptor agonists

CABERGOLINE tablet Spojené štáty - angličtina - NLM (National Library of Medicine)

cabergoline tablet

greenstone llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with

CABERGOLINE tablet Spojené štáty - angličtina - NLM (National Library of Medicine)

cabergoline tablet

par pharmaceutical, inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings).

CABERGOLINE tablet Spojené štáty - angličtina - NLM (National Library of Medicine)

cabergoline tablet

teva pharmaceuticals usa, inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).

Cabergoline Actavis Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

cabergoline actavis

teva pharma (new zealand) limited - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose leucine - prevention of the onset of lactation in the puerperium only for clearly defined medical reasons: arrow - cabergoline is indicated for the inhibition of physiological lactation soon after delivery. 1. after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. 2. after stillbirth or abortion. treatment of hyperprolactinaemic disorders: cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.

CABERGOLINE APOTEX cabergoline 500 micrograms tablets bottle Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cabergoline apotex cabergoline 500 micrograms tablets bottle

arrotex pharmaceuticals pty ltd - cabergoline, quantity: 500 microgram - tablet - excipient ingredients: lactose; magnesium stearate - ? inhibition of physiological lactation ,cabergoline is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons. ,? treatment of hyperprolactinaemic disorders ,cabergoline is indicated for the treatment of pathological hyperprolactinaemia.

Cabergoline 1 mg Tablets Írsko - angličtina - HPRA (Health Products Regulatory Authority)

cabergoline 1 mg tablets

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

Cabergoline 2 mg Tablets Írsko - angličtina - HPRA (Health Products Regulatory Authority)

cabergoline 2 mg tablets

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline